Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular and Molecular Biology

Abstract 3209: The WRN RecQ helicase acts as a tumor suppressor in pancreatic adenocarcinoma

Stephen G. Chun, Nelson S. Yee, Fang Qi, Richard Allsopp, Philip M. Davy, Keith S. Fong, Michele Carbone and Peter K. Bryant-Greenwood
Stephen G. Chun
1University of Hawaii, Honolulu, HI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nelson S. Yee
2University of Iowa, Iowa City, IA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fang Qi
1University of Hawaii, Honolulu, HI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Allsopp
1University of Hawaii, Honolulu, HI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip M. Davy
1University of Hawaii, Honolulu, HI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith S. Fong
1University of Hawaii, Honolulu, HI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Carbone
1University of Hawaii, Honolulu, HI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter K. Bryant-Greenwood
1University of Hawaii, Honolulu, HI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-3209 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

The vast majority of pancreatic adenocarcinoma is diagnosed in the geriatric population, and genes involved in cellular senescence such as the WRN-encoded RecQ helicase/exonuclease may be involved in pancreatic oncogenesis. Accumulating evidence suggests that WRN is a tumor suppressor gene (TSG), as a variety of cancers including pancreatic adenocarcinoma are associated with its epigenetic silencing or loss-of-function mutations. We hypothesize that wild-type WRN protects pancreatic epithelia from malignant transformation by regulating cell cycle progression and cell growth. First, we characterized a pancreatic adenocarcinoma cell line established from a human cadaver with Werner's syndrome (WS-Panc). WS-Panc had two loss-of-function mutations of WRN, formed adherent colonies in vitro, and expressed the pancreatic ductal epithelial marker cytokeratin 7. No oncogenic mutations of the epidermal growth factor receptor (EGFR), K-Ras nor B-Raf were detected by polymerase chain reaction (PCR), and immunologic assays revealed over-expression of lysyl oxidase-like 2, p53, and ß-catenin in WS-Panc. Fluorescent in situ hybrdization showed that WS-Panc over-expresses EGFR. Cytogenetic analyses showed normal karyotype. Strong telomerase activity was detected in WS-Panc by the Telomere Repeat Amplification Protocol. To test the hypothesis that WRN is a TSG, we forced ectopic expression of wild-type WRN in WS-Panc and are analyzing the biological properties and molecular features of transfected cells. Consistent with an anti-proliferative effect, wild-type WRN mRNA levels are uniformly repressed in a panel of sporadic pancreatic cancer cell lines from the American Type Culture Collection as shown by quantitative real-time PCR. In summary, we provide evidence that WRN is a TSG in pancreatic epithelia using WS-Panc and other pancreatic cancer cell lines. WS-Panc is the first cancer cell line carrying WRN loss-of-function mutations that represents a unique translational resource to elucidate WRN in the neoplastic state. Ongoing investigation of WRN in primary pancreatic cancer tissue and tumor models in vivo are expected to elucidate mechanistic links between aging and pancreatic cancer for the purpose of developing efficacious interventional strategies.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3209.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 3209: The WRN RecQ helicase acts as a tumor suppressor in pancreatic adenocarcinoma
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 3209: The WRN RecQ helicase acts as a tumor suppressor in pancreatic adenocarcinoma
Stephen G. Chun, Nelson S. Yee, Fang Qi, Richard Allsopp, Philip M. Davy, Keith S. Fong, Michele Carbone and Peter K. Bryant-Greenwood
Cancer Res April 15 2010 (70) (8 Supplement) 3209; DOI: 10.1158/1538-7445.AM10-3209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 3209: The WRN RecQ helicase acts as a tumor suppressor in pancreatic adenocarcinoma
Stephen G. Chun, Nelson S. Yee, Fang Qi, Richard Allsopp, Philip M. Davy, Keith S. Fong, Michele Carbone and Peter K. Bryant-Greenwood
Cancer Res April 15 2010 (70) (8 Supplement) 3209; DOI: 10.1158/1538-7445.AM10-3209
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cellular and Molecular Biology

  • Abstract SY29-01: Functions of wild type and mutant p53
  • Abstract SY34-02: The impact of O2 availability on human cancer
  • Abstract SY19-01: Cell to cell variability in the responses of tumor cells to death ligands
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Telomeres and the Mechanisms of Senescence and Aging

  • Abstract 3213: GRHL2 enhances hTERT transcription by inhibiting promoter DNA methylation at 5’ CpG island
  • Abstract 3201: Identification of the type 2 cystatins (SA/SN) as a novel biomarkers for stress-induced senescence in human non-small cell lung cancer lines
  • Abstract 3219: Heterocyclic cations: Highlighting the importance of selectivity in biologically relevant quadruplex DNA recognition and binding
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement